Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men - PubMed (original) (raw)
Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men
P M Ridker et al. Circulation. 2000.
Abstract
Background: Interleukin-6 (IL-6) plays a central role in inflammation and tissue injury. However, epidemiological data evaluating the role of IL-6 in atherogenesis are sparse.
Methods and results: In a prospective study involving 14 916 apparently healthy men, we measured baseline plasma concentration of IL-6 in 202 participants who subsequently developed myocardial infarction (MI) and in 202 study participants matched for age and smoking status who did not report vascular disease during a 6-year follow-up. Median concentrations of IL-6 at baseline were higher among men who subsequently had an MI than among those who did not (1.81 versus 1. 46 pg/mL; P=0.002). The risk of future MI increased with increasing quartiles of baseline IL-6 concentration (P for trend <0.001) such that men in the highest quartile at entry had a relative risk 2.3 times higher than those in the lowest quartile (95% CI 1.3 to 4.3, P=0.005); for each quartile increase in IL-6, there was a 38% increase in risk (P=0.001).This relationship remained significant after adjustment for other cardiovascular risk factors, was stable over long periods of follow-up, and was present in all low-risk subgroups, including nonsmokers. Although the strongest correlate of IL-6 in these data was C-reactive protein (r=0.43, P<0.001), the relationship of IL-6 with subsequent risk remained after control for this factor (P<0.001).
Conclusions: In apparently healthy men, elevated levels of IL-6 are associated with increased risk of future MI. These data thus support a role for cytokine-mediated inflammation in the early stages of atherogenesis.
Similar articles
- Dietary inflammatory index and risk of first myocardial infarction; a prospective population-based study.
Bodén S, Wennberg M, Van Guelpen B, Johansson I, Lindahl B, Andersson J, Shivappa N, Hebert JR, Nilsson LM. Bodén S, et al. Nutr J. 2017 Apr 4;16(1):21. doi: 10.1186/s12937-017-0243-8. Nutr J. 2017. PMID: 28376792 Free PMC article. - Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men.
Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Ridker PM, et al. Lancet. 1998 Jan 10;351(9096):88-92. doi: 10.1016/S0140-6736(97)09032-6. Lancet. 1998. PMID: 9439492 Clinical Trial. - Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002.
Koenig W, Khuseyinova N, Baumert J, Thorand B, Loewel H, Chambless L, Meisinger C, Schneider A, Martin S, Kolb H, Herder C. Koenig W, et al. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2745-51. doi: 10.1161/01.ATV.0000248096.62495.73. Epub 2006 Sep 28. Arterioscler Thromb Vasc Biol. 2006. PMID: 17008587 - Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction.
Fisman EZ, Benderly M, Esper RJ, Behar S, Boyko V, Adler Y, Tanne D, Matas Z, Tenenbaum A. Fisman EZ, et al. Am J Cardiol. 2006 Jul 1;98(1):14-8. doi: 10.1016/j.amjcard.2006.01.045. Epub 2006 Apr 27. Am J Cardiol. 2006. PMID: 16784912 - IL-8 plasma concentrations and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study.
Boekholdt SM, Peters RJ, Hack CE, Day NE, Luben R, Bingham SA, Wareham NJ, Reitsma PH, Khaw KT. Boekholdt SM, et al. Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1503-8. doi: 10.1161/01.ATV.0000134294.54422.2e. Epub 2004 Jun 3. Arterioscler Thromb Vasc Biol. 2004. PMID: 15178568
Cited by
- Role of C-Reactive Protein, An Inflammatory Biomarker in The Development of Atherosclerosis and Its Treatment.
Prasad K. Prasad K. Int J Angiol. 2024 Jul 18;33(4):271-281. doi: 10.1055/s-0044-1788296. eCollection 2024 Dec. Int J Angiol. 2024. PMID: 39502349 Review. - Management of a Patient with Cardiovascular Disease Should Include Assessment of Primary and Secondary Immunodeficiencies: Part 2-Secondary Immunodeficiencies.
Napiórkowska-Baran K, Doligalska A, Drozd M, Czarnowska M, Łaszczych D, Dolina M, Szymczak B, Schmidt O, Bartuzi Z. Napiórkowska-Baran K, et al. Healthcare (Basel). 2024 Oct 4;12(19):1977. doi: 10.3390/healthcare12191977. Healthcare (Basel). 2024. PMID: 39408157 Free PMC article. Review. - Mendelian Randomization Studies in Atherosclerotic Cardiovascular Diseases.
Ko DS, Kim YH. Ko DS, et al. J Lipid Atheroscler. 2024 Sep;13(3):280-291. doi: 10.12997/jla.2024.13.3.280. Epub 2024 May 27. J Lipid Atheroscler. 2024. PMID: 39355404 Free PMC article. Review. - The chemical composition of secondary organic aerosols regulates transcriptomic and metabolomic signaling in an epithelial-endothelial in vitro coculture.
Offer S, Di Bucchianico S, Czech H, Pardo M, Pantzke J, Bisig C, Schneider E, Bauer S, Zimmermann EJ, Oeder S, Hartner E, Gröger T, Alsaleh R, Kersch C, Ziehm T, Hohaus T, Rüger CP, Schmitz-Spanke S, Schnelle-Kreis J, Sklorz M, Kiendler-Scharr A, Rudich Y, Zimmermann R. Offer S, et al. Part Fibre Toxicol. 2024 Sep 19;21(1):38. doi: 10.1186/s12989-024-00600-x. Part Fibre Toxicol. 2024. PMID: 39300536 Free PMC article. - IL-6R (trans-signaling) is a key regulator of reverse cholesterol transport in lipid-laden macrophages.
Al-Rashed F, AlSaeed H, Almansour N, Al-Mulla F, Hannun YA, Ahmad R. Al-Rashed F, et al. Clin Immunol. 2024 Oct;267:110351. doi: 10.1016/j.clim.2024.110351. Epub 2024 Aug 30. Clin Immunol. 2024. PMID: 39216780
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials